Unbound free fatty acids and heart-type fatty acid-binding protein: Diagnostic assays and clinical applications

被引:105
作者
Azzazy, HME
Pelsers, MMAL
Christenson, RH
机构
[1] Amer Univ Cairo, Dept Chem, Cairo 11511, Egypt
[2] Amer Univ Cairo, Sci & Technol Res Ctr, Sch Sci & Engn, Cairo, Egypt
[3] Maastricht Univ, CARIM, Dept Mol Genet, Maastricht, Netherlands
[4] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA
[5] Univ Maryland, Sch Med, Dept Med & Res Technol, Baltimore, MD 21201 USA
关键词
D O I
10.1373/clinchem.2005.056143
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: A biomarker that reliably detects myocardial ischemia in the absence of necrosis would be useful for initial identification of unstable angina patients and for differentiating patients with chest pain of an etiology other than coronary ischemia, and could provide clinical utility complementary to that of cardiac troponins, the established markers of necrosis. Unbound free fatty acids (FFA(u)) and their intracellular binding protein, heart-type fatty acid-binding protein (H-FABP), have been suggested to have clinical utility as indicators of cardiac ischemia and necrosis, respectively. Methods: We examined results of clinical assessments of FFAu and H-FABP as biomarkers of cardiac ischemia and necrosis. Data published on FFAu and H-FABP over the past 30 years were used as the basis for this review. Results: Although little clinical work has been done on FFA(u) since the initial reports, recent studies documented an association between increased serum FFAs and ventricular dysrhythmias and death in patients with acute myocardial infarction (AMI). Recent data suggest that serum FFA(u) concentrations increase well before markers of cardiac necrosis and are sensitive indicators of ischemia in AMI. H-FABP is abundant in cardiac muscle and is presumed to be involved in myocardial lipid homeostasis. Similar to myoglobin, plasma H-FABP increases within 3 h after AMI and returns to reference values within 12-24 h. Conclusions: FFA(u) may have a potential role in identifying patients with cardiac ischemia. H-FABP is useful for detecting cardiac injury in acute coronary syndromes and predicting recurrent cardiac events in acute coronary syndromes and in congestive heart failure patients. Assays are available for both markers that could facilitate further clinical investigations to assess their possible roles as markers of cardiac ischemia and/or necrosis. (c) 2006 American Association for Clinical Chemistry.
引用
收藏
页码:19 / 29
页数:11
相关论文
共 77 条
[1]   Myocardial infarction redefined -: A consensus Document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction [J].
Alpert, JS ;
Antman, E ;
Apple, F ;
Armstrong, PW ;
Bassand, JP ;
de Luna, AB ;
Beller, G ;
Breithardt, G ;
Chaitman, BR ;
Clemmensen, P ;
Falk, E ;
Fishbein, MC ;
Galvani, M ;
Garson, A ;
Grines, C ;
Hamm, C ;
Jaffe, A ;
Katus, H ;
Kjekshus, J ;
Klein, W ;
Klootwijk, P ;
Lenfant, C ;
Levy, D ;
Levy, RI ;
Luepker, R ;
Marcus, F ;
Näslund, U ;
Ohman, M ;
Pahlm, O ;
Poole-Wilson, P ;
Popp, R ;
Alto, P ;
Pyörälä, K ;
Ravkilde, J ;
Rehnquist, N ;
Roberts, W ;
Roberts, R ;
Roelandt, J ;
Rydén, L ;
Sans, S ;
Simoons, ML ;
Thygesen, K ;
Tunstall-Pedoe, H ;
Underwood, R ;
Uretsky, BF ;
Van de Werf, F ;
Voipio-Pulkki, LM ;
Wagner, G ;
Wallentin, L ;
Wijns, W .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) :959-969
[2]  
[Anonymous], 1989, NEW ENGL J MED, V320, P618
[3]   Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome [J].
Apple, FS ;
Wu, AHB ;
Mair, J ;
Ravkilde, J ;
Panteghini, M ;
Tate, J ;
Pagani, F ;
Christenson, RH ;
Mockel, M ;
Danne, O ;
Jaffe, AS .
CLINICAL CHEMISTRY, 2005, 51 (05) :810-824
[4]   FAILURE OF NEW BIOCHEMICAL MARKERS TO EXCLUDE ACUTE MYOCARDIAL-INFARCTION AT ADMISSION [J].
BAKKER, AJ ;
KOELEMAY, MJW ;
GORGELS, JPMC ;
VANVLIES, B ;
SMITS, R ;
TIJSSEN, JGP ;
HAAGEN, FDM .
LANCET, 1993, 342 (8881) :1220-1222
[5]  
Chan CPY, 2004, Z KARDIOL, V93, P388, DOI 10.1007/s00392-004-0080-6
[6]   Development of a quantitative lateral-flow assay for rapid detection of fatty acid-binding protein [J].
Chan, CPY ;
Sum, KW ;
Cheung, KY ;
Glatz, JFC ;
Sanderson, JE ;
Hempel, A ;
Lehmann, M ;
Renneberg, I ;
Renneberg, R .
JOURNAL OF IMMUNOLOGICAL METHODS, 2003, 279 (1-2) :91-100
[7]   Early diagnosis of acute myocardial infarction using immunosensors and immunotests [J].
Chan, CPY ;
Cheng, WS ;
Glatz, JFC ;
van der Voort, D ;
Sanderson, JE ;
Hempel, A ;
Lehmann, M ;
Renneberg, I ;
Renneberg, R .
ANALYTICAL LETTERS, 2003, 36 (09) :1987-2004
[8]  
CHEN IW, 1980, CLIN CHEM, V26, P1864
[9]   Measurement of myocardial infarct size from plasma fatty acid-binding protein or myoglobin, using individually estimated clearance rates [J].
de Groot, MJM ;
Wodzig, KWH ;
Simoons, ML ;
Glatz, JFC ;
Hermens, WT .
CARDIOVASCULAR RESEARCH, 1999, 44 (02) :315-324
[10]   Assessment of coronary reperfusion in patients with myocardial infarction using fatty acid binding protein concentrations in plasma [J].
de Groot, MJM ;
Muijtjens, AMM ;
Simoons, ML ;
Hermens, WT ;
Glatz, JFC .
HEART, 2001, 85 (03) :278-285